drugset / Trial / NCT05131763
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2022-12-01
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NKG2D-based CAR T-cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | NKG2D-based CAR T-cells | Cell therapy | 1e+07 cells/kg | Intravenous |